Article: UC researcher uses historical control group for new osteoporotic fracture analysis.

2002 AUG 22 - (NewsRx.com & NewsRx.net) -- In a new analysis of a study funded by Procter & Gamble Pharmaceuticals, Nelson Watts, MD, professor of medicine at the University of Cincinnati (UC) and director of the UC Bone Health and Osteoporosis Center, has applied an innovative new method for analyzing fracture efficacy for an osteoporosis therapy in a study that was conducted without a placebo control group.

The original study was intended to compare two different dose forms of Actonel (risedronate sodium tablets) for the treatment and prevention of osteoporosis in postmenopausal women, and thus did not have a placebo control group.

Watts constructed a ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!